Laval University

ulaval.ca

Total trials

372

Active

74

Phase 3

15

Total enrollment

107,377

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 7 of 7 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Naltrexone/Bupropion1
Activated Charcoal1
Cyproheptadine 4 Mg Oral1
Heparin2
Incretin-Based Treatment1
Lemborexant1
Mepolizumab1

Next readouts

  • 2024-12-31
  • 2026-06-01
  • 2026-09
  • 2027-01
  • 2027-02
  • 2028-03
  • 2028-06

Top conditions

  • Obesity25
  • Asthma22
  • Metabolic Syndrome16
  • Chronic Obstructive Pulmonary Disease15
  • Insulin Resistance9
  • Cardiovascular Disease8
  • Overweight8
  • Respiratory Failure7

Frequently asked questions about Laval University

How many clinical trials does Laval University have on ClinicalTrials.gov?
Laval University is listed as the lead sponsor on 372 clinical trials in ClinicalTrials.gov, 74 of which are currently active (recruiting, enrolling, or ongoing).
How many of Laval University's trials are in Phase 3?
15 of Laval University's trials are in Phase 3, spread across 7 active drug programs.
What therapeutic areas does Laval University focus on?
Laval University's most-studied conditions on ClinicalTrials.gov are Obesity, Asthma, Metabolic Syndrome, Chronic Obstructive Pulmonary Disease, Insulin Resistance.
When are Laval University's next clinical trial readouts?
Laval University has 7 upcoming primary-completion readouts tracked here; the soonest is “Optimal Cardiopulmonary Bypass and Anticoagulation Management Strategies in Obese Patients Undergoing Cardiac Surgery”, expected around 2024-12-31.